Pharmacokinetics of lisinopril.
The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food. The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours. Steady state is attained after two daily doses (every 24 hours) in healthy volunteers. The drug is not metabolized but is eliminated via the kidneys. Lisinopril probably undergoes glomerular filtration, tubular secretion, and tubular reabsorption. There is no pharmacokinetic interaction between lisinopril and furosemide.
Beermann
B
B
Department of Drugs, National Board of Health and Welfare, Uppsala, Sweden.
D000284:Administration, Oral; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D001682:Biological Availability; D004347:Drug Interactions; D004656:Enalapril / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D005502:Food; D005665:Furosemide / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D017706:Lisinopril; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D005665:Furosemide; D017706:Lisinopril